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Dairy attentuates oxidative and inﬂammatory stress in metabolic
syndrome
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ABSTRACT
Background: Oxidative and inﬂammatory stress are elevated in
obesity and are further augmented in metabolic syndrome. We showed
previously that dairy components suppress the adipocyte- and macro-
phage-mediated generation of reactive oxygen species and inﬂamma-
tory cytokines and systemic oxidative and inﬂammatory biomarkers in
obesity.
Objective: The objective of this study was to determine the early
(7 d) and sustained (4 and 12 wk) effects of adequate-dairy (AD) com-
pared with low-dairy (LD) diets in subjects with metabolic syndrome.
Design: Forty overweight and obese adults with metabolic syndrome
were randomly assigned to receive AD (3.5 daily servings) or LD
(,0.5 daily servings) weight-maintenance diets for 12 wk. Oxidative
and inﬂammatory biomarkers were assessed at 0, 1, 4, and 12 wk as
primary outcomes; body weight and composition were measured at 0,
4 ,a n d1 2w ka ss e c o n d a r yo u t c o m e s .
Results: AD decreased malondialdehyde and oxidized LDL at 7 d
(35% and 11%, respectively; P , 0.01), with further decreases by
12 wk. Inﬂammatory markers were suppressed with intake of AD,
with decreases in tumor necrosis factor-a at 7 d and further reductions
t h r o u g h1 2w k( 3 5 % ;P , 0.05); decreases in interleukin-6 (21%;
P , 0.02) and monocyte chemoattractant protein 1 (14% decrease at
4 wk, 24% decrease at 12 wk; P , 0.05); and a corresponding 55%
increase in adiponectin at 12 wk (P , 0.01). LD exerted no effect on
oxidative or inﬂammatory markers. Diet had no effect on body
weight; however, AD signiﬁcantly reduced waist circumference and
trunk fat (P , 0.01 for both), and LD exerted no effect.
Conclusion: An increase in dairy intake attenuates oxidative and
inﬂammatory stress in metabolic syndrome. This trial was regis-
tered at clinicaltrials.gov as NCT01266330. Am J Clin Nutr
2011;94:422–30.
INTRODUCTION
Oxidative stress is augmented in obesity; the addition of
oxidants suppresses the adipose tissue expression of adiponectin
and increases the expression of inﬂammatory cytokines, whereas
antioxidants exert the opposite effect (1–3). Moreover, the oxi-
dative and inﬂammatory burden is further magniﬁed in metabolic
syndrome, which markedly increases the risk of diabetes and
cardiovascular and cerebrovascular disease in obese adults (4–6).
This observation may explain the disproportionate increase in
coronary heart disease (CHD) risk that results when metabolic
syndrome accompanies obesity, compared with uncomplicated
obesity (7). It was reported that the oxidative and inﬂammatory
burden was augmented in otherwise healthy obese subjects with
metabolic syndrome compared with body mass index (BMI; in
kg/m
2)–matched obese subjects without metabolic syndrome
(8).
Although the effect of diet composition on the oxidative and
inﬂammatory burden has not been well studied, data from the
Nurses’ Health Study indicate that a diet high in soft drinks,
reﬁned grains, and processed meat is positively associated with
inﬂammatory biomarkers (9). Additional data from the Nurses’
Health Study show an inverse relation between a “prudent” di-
etary pattern, which includes low-fat dairy products, and in-
ﬂammatory biomarkers (10). Similar associations were reported
in the Multi-Ethnic Study of Atherosclerosis (MESA) study (11),
in a cross-sectional study of dietary patterns in middle-aged
Iranian women (12), and in the ATTICA study of .3000 healthy
Greek adults (13). Additionally, Miller et al (14) showed a dairy-
rich diet to signiﬁcantly reduce urinary isoprostanes in a 3-mo
randomized controlled trial of the Dietary Approaches to Stop
Hypertension (DASH) diet in overweight adults. In contrast,
Wennersberg et al (15) observed no change in oxidative or in-
ﬂammatory biomarkers in a 6-mo randomized trial of 3–5 dairy
servings/d in patients with metabolic syndrome. However, the
control group continued habitual consumption of ’200 g milk/d,
which possibly minimized the effects of the supplemental dairy.
We showed recently that calcitriol augments adipocyte and
muscle oxidative and inﬂammatory stress, whereas dietary calcium–
induced suppression of calcitriol decreases the oxidative and in-
ﬂammatory burden in a mouse model of obesity (7, 16). Moreover,
dairy exerted a signiﬁcantly greater effect than calcium per se, and
retrospective assessment of archival serum samples from prior
clinical trials indicates a comparable protective effect of dairy in
obese humans (17). We conﬁrmed these ﬁndings in a recent ran-
domized crossover trial in otherwise healthy overweight and obese
adults, and showed that dairy-based smoothies, but not soy-based
smoothies, signiﬁcantly reduced circulating biomarkers of oxidative
stress (malondialdehyde and 8-isoprostane F2a) and inﬂammation
[tumor necrosis factor-a (TNF-a), interleukin-6, monocyte che-
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creased adiponectin (18). Accordingly, we conducted the present
study to determine whether dairy-rich diets can similarly at-
tenuate the elevated oxidative and inﬂammatory burden associ-
ated with metabolic syndrome; we studied early (7-d) and later
(28- and 84-d) times to ascertain whether these effects occur
before any diet-induced weight changes.
SUBJECTS AND METHODS
Participants
Fortyoverweightandobeseadults(19menand21women)with
a diagnosis of metabolic syndrome as deﬁned by National Cho-
lesterolEducationProgram,AdultTreatmentPanelIII(NCEPATP
III) criteria (19) were recruited from the staff and student pop-
ulation of the University of Tennessee and the staff and patient
population of the University of Tennessee Medical Center via
posters, and from the Knoxville area via electronic and print
advertisements in the Knoxville. The criteria included the pres-
ence of  3 of the following risk determinants: abdominal obesity
(a waist circumference of  102 cm for men and  88 cm for
women), high triglycerides ( 150 mg/dL), low HDL cholesterol
(,40 mg/dL for males and ,50 mg/dL for females), elevated
blood pressure ( 130/ 85 mm Hg), and high fasting glucose
( 100 mg/dL). To qualify, subjects must have maintained a stable
weight, with  3 kg weight loss in the 3 mo that preceded the
study. Subjects were excluded for the following reasons: type II
diabetes that required the use of any oral antidiabetic agent and/or
insulin; active gastrointestinal disorders or eating disorders; ad-
verse response to dairy foods; recent (past 12 wk) use of tobacco,
pharmacotherapeutic agents, over-the-counter antiobesity agents,
or psychotropic medication; recent initiation of an exercise pro-
gram; recent initiation/change in hormonal birth control or hor-
mone replacement therapy; or pregnancy/lactation.
Design
Two weight-maintenance diets were presented to the subject
groups in a randomized parallel-group design. A low-dairy diet
(,0.5 serving/d) was studied against an adequate-dairy diet (.3.5
servings daily). Each diet was presented for 84 d, with measure-
ments (described below) taken at baseline and on day 7, day 14,
day 28, and day 84. This study was approved from an ethical
standpoint by the Institutional Review Board of the University of
Tennessee-Knoxville; standardized informed consent was obtained
from all subjects, and the research was conducted in accordance
with the ethical standards outlined in the Helsinki Declaration.
This study is registered at clinicaltrials.gov (registration ID no.
NCT01266330).
Sample size
Sample size was estimated based on the following consid-
erations. Our initial pilot data, which evaluated the effects of dairy
on circulating adiponectin and CRP, showed signiﬁcant effects
with a sample size of 16–18/group. Power calculations based on
the variability of the CRP data indicated a sample size of 7/group
would be sufﬁcient to detect a 20% difference in CRP and that
a sample size of 9/group would be sufﬁcient to detect a 20%
difference in adiponectin. This suggested that a sample size of 10
per treatment (20 total) would provide sufﬁcient power for the
primary outcome variables. However, the present study includes
a broader BMI range than the pilot studies (25.0–39.9 compared
with 30–34.9), and a higher variability in baseline values for
oxidative and inﬂammatory variables was consequently antici-
pated. Accordingly, the sample size estimate was increased 2-fold,
to 40 (n = 20/group).
Diets
Subjects were randomly assigned to either a low-dairy (,0.5
dairy serving/d and ,600 mg calcium/d) or adequate-dairy (.3.5
dairy servings/d,  1200 mg calcium/d) weight-maintenance diet.
Maintenance levels of calorie intake were determined from the
measurement of resting metabolic rate (RMR) via indirect calo-
rimetry. Total daily energy expenditure and maintenance energy
requirements were calculated as 1.2–1.4 times RMR, depending
on the level of physical activity. The diets were constructed to
provide amounts of macronutrient and ﬁber comparable to the
approximate average consumption in the United States (fat, ’35%
of total kcal; carbohydrates, ’49%; protein, ’16%; and ﬁber, 8–
12 g/d). Nutritional supplements were not permitted, and caffeine
intake was maintained at a constant level (individualized for each
patient, based on baseline assessment).
Subjects consuming the adequate-dairy diet received 3 daily
servings of dairy, each of which provided 300–350 mg calcium
and 8–10 g dairy protein. Dairy-derived calcium totaled 1000–
1050mg/dand dairy-derived proteintotaled28–35 g/d.The dairy
products were provided to each subject based on individual
choice from a standardized list, with adjustments made to the
remainder of the diet to ensure that subject choices did not alter
macronutrientintake.Twoofthe3dairyservingsconsumeddaily
by those on the adequate-dairy diet were milk and/or yogurt, to
ensure sufﬁcient consumption of whey proteins.
Subjects consuming the low-dairy diet were provided with 3
daily servings of prepackaged nondairy foods selected from a
standardized list,which included a combination of luncheon meats
(low-sodium varieties), soy-based luncheon meat substitutes, pack-
aged fruit cups, granola bars, and peanut butter crackers. Each
s er v i n gp ro v i d e dn om or et h an8 go fp r o t e i na n d5 0m gc al ci u m ,
and adjustments were made to the remainder of the diet to ensure
that subject choices did not alter macronutrient intake. All other
foods were purchased by the participants.
Subjects were given individual instruction, counseling, and
assessment regarding dietary adherence. All subjects maintained
complete diet and physical activity diaries throughout the study.
Compliance
Review of diet records and product package return was used to
assess compliance with the protocol, as follows:
Low dairy:  600 mg calcium/d and  0.5 servings of dairy/d
Adequate dairy:  1000 mg calcium/d and  3.5 servings of
dairy/d
All subjects: product package return (dairy or dairy substitute
foods) to reﬂect  80% consumption of provided foods
Compliance was assessed weekly, and compliance with all
criteria was required to consider a subject compliant within any
given week. Subjects were considered to be compliant for the
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9 wk) of the 12 active treatment weeks.
Anthropometric measures
Body weight and waist circumference were measured weekly,
with subjects wearing street clothes with no shoes, outerwear, or
accessories. Body weight was measured with a calibrated scale.
Height was measured with a wall-mounted stadiometer. Waist cir-
cumference was measured in the standing position with measure-
ments obtained midway between the lateral lower rib margin and
the ileac crest. Two measurements were taken midexhalation
and the average was recorded.
Body composition
Totalfatmass,trunkfatmass,andpercentageleanandfatmass
were assessed via dual-energy X-ray absorptiometry at baseline
and on day 28 and day 84. A LUNAR Prodigy dual-energy X-ray
absorptiometry system (GE Health Care, Madison, WI), main-
tained and calibrated by LUNAR staff annually, was used. A
spine phantom was assessed every day to determine whether any
drift in the machine occurred, followed by the daily calibration
block; spine phantom variation was ,3% throughout the study.
Blood pressure
Bloodpressureandheartratemeasurementsweretakenafterthe
patient had beenseatedinanupright position inachair for  5m i n
with the arm supported at heart level. Blood pressure was mea-
sured with an appropriately sized cuff with the use of a standard
calibrated sphygmomanometer on the same arm for every mea-
surement. Three readings,  1 min apart, were taken and the av-
erage of these 2 was reported. Blood pressure and heart rate were
measured weekly.
Reactive oxygen species/oxidative stress
Plasma malondialdehyde and plasma oxidized LDL were mea-
suredatbaselineandonday7,day28,andday84.Malondialdehyde
was measured with the use of a ﬂuorometric assay based on the
method of Yagi (20), and plasma oxidized LDL was measured by
enzyme-linked immunosorbent assay (Assay Designs, Ann Arbor, MI;
LincoResearch,St Charles,MO;and Bioscience,SanDiego,CA).
Inﬂammatory markers and cytokines
Plasma samples were collected at baseline and on day 7, day
28, and day 84. Interleukin-6, monocyte chemoattractant protein
1, adiponectin, TNF-a, and CRP concentrations in plasma were
determined by enzyme-linked immunosorbent assay (Assay De-
signs, Linco Research, and Bioscience).
Additional biochemical variables
Plasma glucose, insulin, and fasting lipid proﬁles (cholesterol,
LDL cholesterol, HDL cholesterol, and triglyceride) were mea-
sured at baseline and on day 7, day 28, and day 84. They were
assessed by standard clinical techniques in the clinical laboratory.
Homeostasis model assessment of insulin resistance
The homeostasis model assessment of insulin resistance (HOMA-
IR) was used as a screening index of changes in insulin sensitivity.
HOMA-IRwascalculatedviaastandardformulafromfastingplasma
insulin and glucose as follows (21):
HOMA-IR ¼½ insulinðlU=mLÞ3glucose ðmmol=LÞ =22:5 ð1Þ
Biomarker assay variability
Intra-assay variation for the oxidative stress biomarkers and
inﬂammatory stress biomarkers ranged from 4.23% to 7.81%.
Interassay variation ranged from 6.84% to 9.22%.
RMR/substrate oxidation
RMR was determined by indirect calorimetry with the use of
the open-circuit technique between 0600 and 1000 h after a 12-h
fastanda48-habstentionfromexerciseatbaselineandonday84.
RMR was used with a physical activity correction to calculate
energy needs for accurate formulation of each individual’s diet
prescription. Respiratory gas exchange was measured via the
ventilated hood technique with the use of a SensorMedics Vmax
29n metabolic cart (SensorMedics, Anaheim, CA).
After a urinary void, subjects rested quietly in the supine
position for 30 min in a semidarkened, thermoneutral (21–24C)
room. Subjects had a clear, ventilated respiratory canopy placed
over the head, remained in a quiet, supine position, and breathed
normally until steady state was reached (normally 20–45 min).
Criteria for a valid RMR was  15 min of steady state, as deﬁned
by ,10% ﬂuctuation in minute ventilation and oxygen consu-
mption and ,5% ﬂuctuation in respiratory quotient. Readings
were taken for the steady state period for determination of resting
energy expenditure, and for a total of 30 min under these basal
conditions for measurement of basal substrate respiratory quo-
tient. The metabolic rate was calculated with the use of the Weir
equations (22). The respiratory quotient was calculated as carbon
dioxide production/oxygen consumption.
A 24-h urine sample was collected for nitrogen analysis for
each assessment to calculate the nonprotein respiratory quotient
TABLE 1
Baseline subject characteristics
1
All subjects Low dairy Adequate dairy
Age (y) 37.0 6 9.9 39.5 6 10.2 34.4 6 9.4
Weight (kg) 94.3 6 12.1 95.6 6 12.5 93.0 6 13.7
Height (cm) 175.4 6 9.0 175.0 6 11.9 175.8 6 5.2
BMI (kg/m
2) 30.7 6 4.1 31.2 6 5.4 30.1 6 4.4
Waist circumference (cm) 103.0 6 5.8 104.7 6 9.6 101.3 6 7.6
Systolic pressure (mm Hg) 127.7 6 8.3 129.8 6 11.5 125.5 6 17.9
Diastolic pressure (mm Hg) 85.9 6 4.0 83.2 6 6.6 82.5 6 10.4
LDL-C (mg/dL) 120.2 6 11.3 132.1 6 24.4 108.3 6 37.5
HDL-C (mg/dL) 47.0 6 6.7 44.6 6 7.3 49.4 6 12.9
Triglycerides (mg/dL) 139.9 6 36.2 142.5 6 83.9 137.2 6 53.0
Sex (M/F) 19/21 9/11 10/10
Ethnicity (n)
African American 7 3 4
Hispanic 9 5 4
White 22 11 11
Other 2 1 1
1 All values are means 6 SDs; n = 20/group. LDL-C, LDL cholesterol;
HDL-C, HDL cholesterol. There were no signiﬁcant group differences.
424 STANCLIFFE ET ALand, subsequently, substrate oxidation. Quality control included
calibrationofthegasanalyzersbeforeeachmeasurementwiththe
use of known gases of 95% oxygen and 5% carbon dioxide.
Statistical analysis
Changes from baseline values were computed for all outcome
variables. Our analysis evaluated differences between treatments
(adequate dairy or low dairy) measured over multiple time points
(days 7, 28, and 84). These data were analyzed with the use of
a repeated-measures approach; data were analyzed with the use of
the PROC MIXED procedure for repeated measures in SAS
(version 9.1; SAS Inc, Cary, NC). The effects of baseline, gender,
compliance, and obesity status were included in the models and,
where signiﬁcant, are shown in the data tables. When these factors
were not signiﬁcant, they were removed from the ﬁnal model.
TABLE 2
Effects of low-dairy (LD) compared with adequate-dairy (AD) diets on body weight, body composition, and waist
circumference in overweight and obese subjects with metabolic syndrome
1
Variable and
obesity status Diet
Change from baseline
Baseline Day 28 Day 84 P value
Weight (kg)
Overweight LD 87.8 6 12.7 2.7 6 2.3 2.4 6 1.2 NS
AD 89.4 6 5.5 21.4 6 0.3 20.1 6 0.1
Obese LD 103.4 6 16.7 20.7 6 1.0 0.0 6 2.6
AD 98.9 6 11.1 20.6 6 1.3 20.6 6 2.1
All LD 95.6 6 12.5 1.0 6 1.3 1.1 6 1.2
AD 93.0 6 13.7 21.0 6 0.7 20.4 6 0.4
BMI (kg/m
2)
Overweight LD 28.4 6 1.3 0.9 6 0.8 0.8 6 0.5 Obesity status, P , 0.001;
diet, NS; day, NS
AD 26.5 6 1.4 20.4 6 0.1 0.0 6 0.3
Obese LD 34.0 6 2.3 0.2 6 0.4 0.0 6 0.7
AD 33.7 6 3.2 20.2 6 0.4 20.2 6 0.6
All LD 31.2 6 5.4 0.3 6 0.4 0.4 6 0.9
AD 30.1 6 4.4 20.3 6 0.2 0.1 6 0.3
Waist (cm)
Overweight LD 103.9 6 9.9 20.3 6 2.4 20.1 6 3.6 Diet, P , 0.03; diet · day,
P , 0.03; obesity status,
NS; day, NS
AD 97.5 6 4.1 21.2 6 2.3 22.9 6 2.3
Obese LD 106.9 6 9.9 0.3 6 0.2 0.5 6 0.5
AD 103.4 6 8.4 21.8 6 0.3 22.6 6 0.8
All LD 104.7 6 9.6 20.3 6 0.3 20.2 6 0.
AD 101.3 6 7.6 21.5 6 0.6 22.8 6 0.8
Fat mass (kg)
Overweight LD 37.8 6 9.1 20.3 6 0.8 1.0 6 1.9 Diet, P , 0.05; diet · obesity
status, P , 0.05; day, NS;
obesity status, NS
AD 37.0 6 5.8 21.9 6 1.0 21.7 6 1.4
Obese LD 42.4 6 7.7 20.2 6 1.4 20.3 6 2.2
AD 41.5 6 7.5 20.4 6 0.4 20.8 6 0.3
All LD 40.8 6 8.6 0.0 6 1.1 0.4 6 1.6
AD 39.1 6 4.2 21.1 6 0.6 21.3 6 0.9
Trunk fat mass (kg)
Overweight LD 21.7 6 3.8 0.4 6 0.3 0.1 6 0.1 Diet, P , 0.02; obesity
status, NS; day, NS
AD 20.4 6 2.7 21.4 6 0.9 21.2 6 0.6
Obese LD 24.2 6 4.8 0.5 6 0.9 1.1 6 1.5
AD 22.3 6 3.9 20.3 6 0.3 21.5 6 0.3
All LD 23.8 6 5.9 0.4 6 0.7 0.6 6 1.0
AD 21.0 6 3.9 20.8 6 0.4 21.4 6 0.7
Lean mass (kg)
Overweight LD 55.2 6 8.3 20.3 6 0.2 20.2 6 1.0 NS
AD 47.8 6 6.6 1.6 6 2.5 1.8 6 2.4
Obese LD 57.6 6 16.5 20.9 6 1.3 0.0 6 1.1
AD 52.6 6 9.3 0.5 6 1.1 0.3 6 1.3
All LD 56.1 6 5.3 20.5 6 1.8 20.1 6 1.2
AD 49.3 6 10.0 1.1 6 0.6 0.8 6 0.8
1 All values are means 6 SDs; n = 40 [20/group (10 overweight and 10 obese)].
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Subject baseline characteristics are shown in Table 1. All
enrolled subjects completed the trial, and 28 met the a priori
compliance criteria described in Subjects and Methods (full
compliance for 9 of the 12 wk of the study); an additional 5
subjects were fully compliant for 8 of the 12 wk of the study.
There was no signiﬁcant change in body weight for either
treatment group, but the adequate-dairy group exhibited a sig-
niﬁcant decrease in fat mass (’1 kg, P , 0.05). Most of this
loss of body fat was accounted for by a decrease in trunk fat
TABLE 3
Effects of low-dairy (LD) compared with adequate-dairy (AD) diets on glucose, insulin, and insulin resistance in overweight and obese subjects with
metabolic syndrome
1
Variable and
obesity status Diet Baseline
Change from baseline
P value Day 7 Day 28 Day 84
Glucose (mmol/L)
Overweight LD 4.84 6 0.39 20.32 6 0.95 0.31 6 0.91 0.38 6 0.61 NS
AD 4.83 6 0.59 20.77 6 0.71 20.63 6 0.46 20.04 6 0.22
Obese LD 5.78 6 2.03 20.98 6 0.26 21.0 6 0.52 20.17 6 0.75
AD 4.40 6 1.00 0.14 6 0.16 20.52 6 0.43 0.03 6 0.17
All LD 5.62 6 1.86 20.65 6 0.24 20.35 6 0.45 0.116-0.51
AD 4.57 6 0.84 20.22 6 0.28 20.57 6 20.32 0.01 6 0.22
Insulin (lU/mL)
Overweight LD 9.47 6 5.89 0.39 6 0.68 2.55 6 2.31 1.65 6 2.46 Diet, P , 0.05; obesity status,
NS; day, NS AD 15.58 6 2.86 24.75 6 1.86 24.692.79 23.32 6 2.22
Obese LD 17.80 6 7.24 4.64 6 4.91 2.85 6 2.42 1.74 6 3.23
AD 13.23 6 2.8 22.29 6 1.80 22.19 6 2.01 23.43 6 2.41
All LD 16.42 6 7.52 2.52 6 4.55 2.64 6 2.87 1.72 6 3.14
AD 14.01 6 5.17 23.51 6 1.18 23.43 6 1.48 23.38 6 1.27
HOMA-IR
Overweight LD 2.94 6 0.24 20.83 6 1.19 20.08 6 1.28 20.28 6 1.05 Diet, P , 0.05; obesity status,
NS; day, NS AD 3.45 6 2.18 21.45 6 0.67 0.08 6 0.26 20.60 6 0.43
Obese LD 4.14 6 3.25 1.41 6 1.32 0.51 6 0.42 2.86 6 2.79
AD 2.78 6 0.94 20.33 6 0.44 20.40 6 0.93 20.58 6 0.66
All LD 3.94 6 2.97 0.92 6 0.46 0.21 6 0.34 1.19 6 0.68
AD 3.05 6 1.48 20.71 6 0.35 20.28 6 0.26 20.59 6 0.34
1 All values are means 6 SDs; n = 40 [20/group (10 overweight and 10 obese)]. HOMA-IR, homeostasis model assessment of insulin resistance.
TABLE 4
Effects of low-dairy (LD) compared with adequate-dairy (AD) diets on blood pressure (BP) and heart rate in overweight and obese subjects with metabolic
syndrome
1
Variable and
obesity status
Change from baseline
P value Diet Baseline Day 7 Day 28 Day 84
Systolic BP (mm Hg)
Overweight LD 133.3 6 8.1 1.5 6 1.0 0.7 6 1.6 0.6 6 1.2 Diet, P , 0.01; diet · day, P , 0.01;
obesity status, NS; day, NS AD 122.4 6 14.1 21.9 6 2.6 22.4 6 2.8 25.1 6 2.6
Obese LD 127.3 6 12.2 21.4 6 2.6 1.5 6 1.7 2.1 6 1.5
AD 127.1 6 18.2 21.7 6 1.2 21.4 6 1.0 29.0 6 2.1
All LD 129.8 6 11.5 0.1 6 1.6 1.3 6 1.4 1.4 6 1.8
AD 125.5 6 17.9 21.8 6 2.2 21.9 6 1.7 27.1 6 3.1
Diastolic BP (mm Hg)
Overweight LD 84.5 6 10.6 3.0 6 2.9 2.0 6 0.9 1.5 6 0.5 Diet · day · obesity status, P , 0.05;
diet, NS; obesity status, NS; day, NS AD 82.1 6 9.3 21.6 6 0.5 3.4 6 3.2 22.9 6 1.0
Obese LD 82.9 6 6.4 20.9 6 2.7 0.5 6 1.9 2.2 6 2.9
AD 82.6 6 11.5 21.3 6 3.8 21.4 6 1.2 25.2 6 2.4
All LD 83.2 6 6.6 1.3 6 1.9 0.8 6 1.4 1.9 6 2.2
AD 82.5 6 10.4 21.5 6 0.7 1.0 6 2.7 24.1 6 1.9
Heart rate (beats/min)
Overweight LD 76.8 6 6.2 21.3 6 2.1 0.7 6 2.1 2.4 6 2.2 NS
AD 84.0 6 6.6 20.1 6 1.1 25.5 6 2.1 29.7 6 3.6
Obese LD 76.4 6 12.9 20.7 6 1.1 0 6 1.6 2.0 6 1.9
AD 76.6 6 8.7 4.6 6 1.8 1.5 6 1.7 25.6 6 2.5
All LD 76.4 6 11.7 21.0 6 1.1 0.5 6 1.8 2.2 6 3.3
AD 79.3 6 8.8 2.3 6 1.6 22.0 6 1.9 27.7 6 2.3
1 All values are means 6 SDs; n = 40 [20/group (10 overweight and 10 obese)].
426 STANCLIFFE ET AL(P , 0.02), which was also reﬂected in the signiﬁcant decrease
in waist circumference, which decreased (3 cm; P , 0.03) as
shown in Table 2. The low-dairy diet exerted no signiﬁcant
effect on body composition, weight, or waist circumference
(Table 2).
The effects of dietary treatment on insulin resistance and blood
pressure are summarized in Tables 3 and 4, respectively. The diets
exerted no signiﬁcant effect on plasma glucose, but the adequate-
dairy diet resulted in a signiﬁcant reduction in plasma insulin that
was manifested at day 7 and maintained through the end of the
study (day 84; P , 0.05). Similarly, the HOMA-IR data showed
a signiﬁcant improvement in insulin sensitivity by day 7, main-
tained through the end of the study (P , 0.05) (Table 3). The
adequate-dairy diet also resulted in a signiﬁcant decrease in sys-
tolic blood pressure (P , 0.01), and this effect increased pro-
gressively from day 7 to day 84 (P , 0.01) (Table 4).T h e
adequate-dairy diet also exerted a signiﬁcant effect on diastolic
blood pressure in the obese subgroup on day 84 (P , 0.05), but
was without effect in the low-dairy group. In general, diet exerted
little effect on plasma lipids, although the adequate-dairy diet
resulted in decreases in plasma cholesterol (P , 0.02) and tri-
glycerides (P , 0.05) in the obese subjects only (data not shown).
The effect of dietary treatments on oxidative stress biomarkers
is summarized in Table 5. The adequate-dairy diet resulted in
signiﬁcant attenuation of oxidative stress, as shown by signiﬁ-
cant decreases in both malondialdehyde and oxidized LDL. By
day 7 there was a 35% decrease in malondialdehyde, which was
maintained through the 12 wk of the study (P , 0.01). Similarly,
oxidized LDL had decreased by 11% by day 7 and progressed to
a 25% reduction by the end of the study (P , 0.02). The low-
dairy diet exerted no signiﬁcant effect on oxidative stress bio-
markers, but there was a signiﬁcant effect of obesity status on
both malondialdehyde and oxidized LDL (P , 0.01 and P ,
0.02, respectively).
The effects of dietary treatments on inﬂammatory markers are
summarized in Table 6. The adequate-dairy diet signiﬁcantly
reduced each of the inﬂammatory stress biomarkers studied. A
signiﬁcant reduction in TNF-a was observed by day 7 in the
adequate-dairy group, with a progressively greater effect seen on
days 28 and 84 (P , 0.01); this effect was more pronounced in
the obese than in the overweight subgroup. Monocyte chemo-
attractant protein 1 was similarly decreased by day 7 for the
adequate-dairy diet, with progressively greater effects shown on
days 28 and 84 (P , 0.02 for the diet and time effects). In-
terleukin-6 was decreased by day 7 on the adequate-dairy diet,
with progressively greater effects shown over time, particularly
in the obese subgroup (P , 0.02). CRP followed a similar trend,
although the effect was initially smaller in magnitude for the
obese subgroup but became signiﬁcantly greater among obese
subjects by the end of the study (P , 0.02 for both the diet effect
and interaction). Overall, the adequate-dairy diet resulted in
a 47% decrease in circulating CRP levels by day 84. Adipo-
nectin was signiﬁcantly increased by the adequate-dairy diet,
with a 25% increase noted by day 7 that progressed to a 53%
increase by day 84 (P , 0.005). This effect was signiﬁcantly
more pronounced in the obese subgroup (P , 0.01).
DISCUSSION
Data from this study show that an increase in dairy intake from
suboptimal to adequate levels (’3.5 servings/d) signiﬁcantly
attenuates both oxidative and inﬂammatory stress in metabolic
syndrome. Notably, although these effects may result, in part,
from reductions in adiposity on higher dairy diets (17, 18), the
rapid onset (within the ﬁrst 7 d of dietary change) suggest that
there is an adiposity-independent effect as well. This is further
supported by our previous evidence that showed direct effects of
dairy components on adipocyte cytokine expression and secre-
tion (23–25).
Our results are at variance with the recent report by Wen-
nersberg et al (15), because they showed no effect of a6-mo dairy
intervention on body composition or oxidative or inﬂammatory
biomarkers in Scandinavian subjects with metabolic syndrome,
although they did ﬁnd an improvement in the HOMA index of
comparable magnitude to that reported here. However, there are
some key design differences between the 2 trials. The Wen-
nersberg (15) study did not control macronutrient and energy
intake, and the dairy intervention group exhibited increases in
TABLE 5
Effects of low-dairy (LD) compared with adequate-dairy (AD) diets on oxidative biomarkers in overweight and obese subjects with metabolic syndrome
1
Biomarker and
obesity status Diet Baseline
Change from baseline
P value Day 7 Day 28 Day 84
Malondialdehyde (nmol/L)
Overweight LD 1.95 6 0.47 0.43 6 0.47 0.59 6 0.37 0.80 6 0.11 Diet, P , 0.01; obesity status,
P , 0.01; day, NS AD 2.80 6 0.53 21.34 6 0.40 20.86 6 0.46 20.81 6 0.44
Obese LD 5.14 6 1.50 20.42 6 1.22 1.13 6 1.47 0.70 6 1.14
AD 4.88 6 1.63 21.51 6 0.83 21.79 6 0.91 21.96 6 0.89
All LD 4.61 6 1.40 20.05 6 0.36 0.86 6 0.74 0.74 6 0.45
AD 4.31 6 1.15 21.42 6 0.51 21.34 6 0.71 21.39 6 0.89
Oxidized LDL (ng/mL)
Overweight LD 389 6 62 110 6 85 38 6 96 72 6 83 Diet, P , 0.02; obesity status,
P , 0.02; diet · day, P , 0.02 AD 249.2 6 72 238 6 33 255 6 19 270 6 28
Obese LD 495 6 74 34 6 86 64 6 78 38 6 70
AD 370 6 89 251 6 38 2105 6 36 295 6 22
All LD 442 6 67 72 6 15 51 6 67 55 6 65
AD 315 6 90 245 6 23 278 6 34 288 6 36
1 All values are means 6 SDs; n = 40 [20/group (10 overweight and 10 obese)].
DAIRY AND INFLAMMATION IN METABOLIC SYNDROME 427energy and fat intakes that were notshown in thepresent study. In
addition, subjects recruited for the present study were not ha-
bitual consumers of dairy products, and those in the control (low-
dairy) group maintained their dairy intake at ,0.5 serving/d and
their calcium intake at ,600 mg/d. In contrast, the baseline
calcium intake of the milk intervention group in the Wenners-
berg (15) study was 815 mg/d, possibly too high to observe an
effect of additional dairy foods. Similarly, van Meijl et al (26)
observed only a reduction of TNF-a and an increase in soluble
TNF-a receptor, but no effects on other inﬂammatory bio-
markers in overweight and obese subjects fed a low-fat dairy
diet for 8 wk. However, the estimated calcium intake of their
control subjects was 931 mg/d, which suggests that they were
already consuming sufﬁcient levels of calcium, leaving little
opportunity for dairy to exert signiﬁcant effects. Notably, a
post hoc analysis of subjects below and above a habitual
calcium intake of 700 mg/d showed a signiﬁcant effect of
the dairy intervention on waist circumference and sagittal
TABLE 6
Effects of low-dairy (LD) compared with adequate-dairy (AD) diets on inﬂammatory biomarkers in overweight and obese subjects with metabolic
syndrome
1
Biomarker and
obesity status Diet Baseline
Change from baseline
Day 7 Day 28 Day 84 P value
TNF-a (nmol/L)
Overweight LD 14.47 6 4.03 0.45 6 0.24 0.36 6 1.54 0.29 6 1.99 Diet, P , 0.01; diet · obesity,
P , 0.01; diet · day, P , 0.01; day, NS;
obesity status, NS
AD 12.47 6 1.61 22.34 6 1.28 22.86 6 1.13 22.62 6 1.18
Obese LD 15.09 6 2.42 1.45 6 1.25 1.58 6 0.70 0.68 6 1.30
AD 18.55 6 1.16 22.29 6 1.58 23.60 6 1.25 27.41 6 0.71
All LD 14.22 6 2.87 0.79 6 0.66 0.98 6 1.69 0.49 6 1.40
AD 17.03 6 3.18 22.31 6 1.44 23.16 6 1.36 25.99 6 2.07
MCP-1 (pg/mL)
Overweight LD 195.2 6 36.2 23.7 6 19.7 210.9 6 11.0 222.1 6 22.7 Diet, P , 0.02; diet · day,
P , 0.02; obesity status, NS; day, NS AD 134.8 6 26.6 212.9 6 18.8 232.1 6 15.9 245.6 6 9.3
Obese LD 160.0 6 47.7 7.0 6 12.1 20.2 6 10.9 28.8 6 22.6
AD 182.5 6 66.8 224.5 6 18.0 239.5 6 24.7 245.5 6 22.7
All LD 165.9 6 45.3 15.3 6 3.0 15.6 6 12.8 25.4 6 23.1
AD 176.6 6 59.8 218.7 6 11.5 235.7 6 19.9 245.3 6 29.9
IL-6 (pg/mL)
Overweight LD 25.3 6 4.3 20.7 6 0.9 22.8 6 2.5 1.8 6 2.2 Diet, P , 0.02; diet · obesity
status · day, P , 0.01; day, NS;
obesity status, NS
AD 31.2 6 3.4 23.7 6 0.9 211.0 6 1.9 29.3 6 1.1
Obese LD 44.2 6 4.1 2.7 6 2.6 0.4 6 1.8 21.3 6 1.5
AD 41.6 6 2.7 211.0 6 2.7 213.4 6 2.3 218.1 6 3.3
All LD 31.8 6 1.6 1.0 6 2.6 21.5 6 2.9 0.3 6 3.8
AD 37.4 6 2.9 28.0 6 2.2 212.2 6 3.2 213.7 6 3.8
CRP (ng/mL)
Overweight LD 29.8 6 19.5 8.6 6 11.6 2.3 6 4.2 4.5 6 9.3 Diet, P , 0.02; diet · obesity
status · day, P , 0.02; obesity status,
NS; day, NS
AD 15.0 6 8.9 26.9 6 4.7 27.6 6 4.1 26.4 6 4.4
Obese LD 27.0 6 15.6 7.6 6 9.7 2.5 6 3.1 26.7 6 11.2
AD 24.5 6 16.6 23.0 6 2.4 23.3 6 2.8 211.7 6 6.6
All LD 24.8 6 15.3 8.1 6 4.9 2.4 6 3.2 21.1 6 5.5
AD 21.9 6 14.5 25.0 6 2.8 25.5 6 3.7 29.1 6 5.3
Adiponectin (ng/mL)
Overweight LD 15.73 6 4.55 2.62 6 2.63 24.02 6 3.72 22.31 6 2.64 Diet, P , 0.01; diet · day, P , 0.021;
diet · obesity status · day, P , 0.01 AD 21.08 6 6.62 3.18 6 2.80 3.19 6 2.62 5.27 6 2.16
Obese LD 22.24 6 7.93 21.62 6 3.37 0.89 6 5.31 23.22 6 4.8
AD 16.85 6 6.09 5.17 6 3.35 6.56 6 2.03 11.82 6 3.06
All LD 21.16 6 7.65 20.55 6 1.82 21.56 6 5.38 22.98 6 1.59
AD 18.26 6 6.32 4.17 6 2.44 4.89 6 2.33 9.01 6 5.64
1 All values are means 6 SDs; n = 40 [20/group (10 overweight and 10 obese)]. TNF-a, tumor necrosis factor-a; MCP-1, monocyte chemoattractant
protein 1; IL-6, interleukin-6; CRP, C-reactive protein.
428 STANCLIFFE ET ALabdominal diameter only in those with habitually low calcium
intakes, but no effect on oxidative or inﬂammatory markers. It is
possible that a lower threshold exists for dairy effects on
these biomarkers, but data to evaluate this concept are not
available.
We showed previously that calcitriol stimulates inﬂammatory
cytokine production in adipocytes (23) and that dietary calcium–
induced suppression of calcitriol attenuates adiposity-induced
inﬂammatory cytokines in a mouse model of obesity (16, 26). We
have also shown comparable effects of dairy foods in humans,
because dairy signiﬁcantly reduced circulating biomarkers of oxi-
dative and inﬂammatory stress in otherwise healthy overweight
and obese adults (16, 18).
We observed few signiﬁcant differences between overweight
and obese subjects. Although increased adiposity is generally
associated with increased oxidative and inﬂammatory stress, the
effects of BMI have been studied previously in the absence of
complicating factors. Thus, the additional inﬂammatory stress
that results from metabolic syndrome appears to exert a greater
effect than the adiposity differences between overweight and
obese subjects. However, the oxidative biomarkers (malondial-
dehyde and oxidized LDL) were both higher in the obese than in
the overweight individuals, and the adequate-dairy diet exerted
signiﬁcantly greater effects on both oxidative biomarkers in the
obese subjects compared with the overweight subjects.
These data also indicate that other components of metabolic
syndrome are signiﬁcantly improved by an increase in dairy food
intake to an adequate level. Numerous studies have shown an
inverse relation between dietary calcium and blood pressure (27–
29), and an increase in dairy intake to adequate levels is a key
component of the DASH diet for blood pressure control (30).
Whereas these effects are attributable, in part, to dietary calcium,
food sources of calcium have consistently exerted greater effects
(30).Inadditiontocalcium,dairycontainsbioactivecomponents,
including angiotensin-converting enzyme inhibitory peptides
(31), that also appear to contribute to these effects. We showed
theadequate-dairy diet to signiﬁcantly reduce systolicpressure in
both overweight and obese participants and to reduce diastolic
pressure in obese, but not overweight, subjects. These data con-
ﬁrmthattheachievementofadequatelevelsofdairyconsumption
attenuates the elevated blood pressure that is typically charac-
teristic of metabolic syndrome.
Previousstudieshavesuggestedthatmilkproteins,particularly
the whey fraction, possess insulinotropic effects in healthy indi-
viduals(32),whereasdatafromtheCARDIA studyshowastrong
inverse association between dairy consumption and abnormal
glucose homeostasis, as well as the development of the insulin re-
sistancesyndrome(33).Furthermore,ahigherintakeoflow-fatdairy
appears toreduce the riskof type 2 diabetes (34–37).However, the
underlying mechanism of this protective effect is not well un-
derstood. Numerous studies have indicated a relation between
calcium and vitamin D insufﬁciency and type 2 diabetes (35), and
calciumhasbeenproposedtoexertadirectrole(34).However,other
dairy components, such as angiotensin-converting enzyme inhibi-
tory peptides, may play a signiﬁcant role (33, 34). Consistent with
these observations, data from the present study suggest that an in-
crease in dairy food intake from suboptimal to adequate levels
resultsinanimprovementininsulinsensitivity,becausecirculating
insulin and HOMA-IR were markedly improved by the adequate-
dairy diet.
Key strengths of this study include the randomized controlled
design, the maintenance of the macronutrient composition in the
diets, and the assessment of early and sustained time points to
isolate the effects of dairy-induced changes in adiposity. Our
ﬁndings are limited by the relatively short duration of the in-
tervention (12 wk), the use of self-report diet records to assess
compliance, and the inability to blind subjects to the use of test
(dairy) compared with control foods. In addition, the design of
this study may have suffered additional confounding because
of the use of readily available foods as control products, some of
which may have contributed constituents that exerted potential
positive (soy, fruit) or negative (luncheon meats, trans fatty acids
in peanut butter crackers) independent effects that were not con-
trolled for. Finally, although our selection criteria of subjects
with very low habitual dairy and calcium intakes strengthens our
design by increasing the likelihood that all subjects started below
anticipated calcium and dairy thresholds for treatment effects,
it also limits the external validity of our ﬁndings, because we cannot
extrapolate these ﬁndings to individuals with more moderate levels
of habitual dairy intake.
Nonetheless, the data from this study support our previous
cellular and mouse data, as well as clinical trial data from over-
weight and obese individuals without metabolic syndrome. No-
tably,theeffectsinmetabolicsyndrome,whichischaracterizedby
a higher level of oxidative and inﬂammatory stress, are greater in
magnitude than we recently reported in otherwise healthy over-
weight and obese individuals (18). The rapid onset of these im-
provementsindicatesthattheyarelikelyindependentofanychanges
in adiposity that may result from dairy-rich diets. Moreover, these
dataalsosuggestthatotherkeycomponentsofmetabolicsyndrome
aresigniﬁcantlyimprovedbyanincrease of dairyfoodintake toan
adequate level.
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